-
- We remain committed to making a contribution to improving health in the developing world.
- We have a research facility dedicated to finding a new, improved treatment for TB.
- We work in partnerships that focus on helping vulnerable communities to combat TB and strengthen healthcare capabilities.
Whilst AstraZeneca remains committed to making a contribution to improving healthcare in the developing world, we believe that real progress can only be made through the commitment of all the related stakeholders, including governments, non-governmental organisations (NGOs) and the international community, as well as the private sector. Only by working together can sustainable improvements be achieved.
The medicines in our range today are not relevant to the treatment of tuberculosis (TB), HIV/AIDS and malaria, the most significant healthcare problems that many developing world countries are currently facing, but we are applying our skills and resources to helping in other ways.
DEDICATED TB RESEARCH
We have a dedicated research facility in Bangalore, India that is focused on finding a new, improved treatment for TB – a major cause of illness and death worldwide, especially in Asia and Africa. AstraZeneca is the only major pharmaceutical company with a research programme in India totally dedicated to TB.
WORKING IN PARTNERSHIP
As well as the availability of appropriate medicines, access to healthcare depends on having a functional healthcare system, trained healthcare workers and effective supply and distribution mechanisms in place to ensure that medicines are used to their full effect as part of overall health management. In some parts of the developing world, this is a particular challenge. To help meet this challenge, we continue to partner with NGOs and other organisations working with local communities to strengthen their frameworks for combating TB and delivering healthcare in a sustainable way.
Key principles for these partnerships are that they:
- Lead to positive, measurable outcomes
- Can be scaled up and potentially replicated to improve outcomes for a greater number
- Deliver a sustainable framework that can ultimately be owned and managed locally, without the need for our support
We also aim to ensure that such partnerships can contribute to our business development, by enabling us to understand better the health needs of, and build important relationships in, markets of the future.
Our current partnerships are primarily focused on helping hard-hit communities in Asia and Africa to combat TB, which is on the increase in these regions, but we also have some programmes in other disease areas and in other countries. You can read more about these partnerships throughout this section of our website.
MILLENNIUM DEVELOPMENT GOALS (MDGs)
We continue to work to align our activities with the United Nations MDGs in areas that are relevant to our business and where we have core expertise. Our TB research supports MDG 6 “Combat HIV/AIDS, malaria and other diseases” and our engagement with Stop TB Partnership and other collaborative efforts supports MDG 8 “Develop a global partnership for development”. Elsewhere in the world, other local partnerships include our Safe Motherhood programme in India, which supports MDG 5 – “Improve maternal health”.
The content of this page was externally assured by Bureau Veritas, February 2009.
Not signed in
Page tools
Share price
- London
-
29.44 GBP - New York
-
44.38 USD - Stockholm
-
315.40 SEK
At 11-Mar-2010 10:44 GMT
Detailed share price